Menopause Hormone Therapy and Longevity

MHT has established benefits for menopausal symptoms and bone. Its risks cannot be described with one number because studies have tested different hormones, routes, and populations. This guide separates those questions and explains what the evidence can say about longevity.

What Menopause Hormone Therapy Is

MHT usually means estrogen used alone or with a progestogen. Systemic estrogen reaches the whole body and treats hot flashes and night sweats. It also prevents bone loss and reduces fractures while it is used ¹.

If you have a uterus, systemic estrogen must be paired with an appropriate progestogen. This protects the endometrium, or uterine lining, from cancer. After a hysterectomy, estrogen can usually be used alone. Low-dose vaginal estrogen is the key exception: it acts mainly in local tissue and generally does not require a progestogen ¹.

The Menopause Society and the European Society of Endocrinology agree on these main indications ¹, ². The first task is to define the symptom target. A local treatment cannot substitute for systemic treatment when hot flashes are the problem.

Choosing the Estrogen, the Progestogen, and the Route

A treatment plan should identify the purpose of each hormone and explain why a specific route fits. Route is particularly important when considering blood-clot risk.

Route. Oral estrogen passes through the liver before reaching the circulation. Transdermal estrogen, delivered by a patch or gel, avoids this first pass. Large observational studies associate transdermal estrogen with less venous-thromboembolism risk than oral estrogen ³. These were not randomized head-to-head trials, so the comparison is informative but not definitive. Patches and gels are not free of risk.

Progestogen. People with a uterus need endometrial protection when using systemic estrogen. The dose and schedule depend on the estrogen regimen and bleeding goals. Breast-cancer risk may also differ by progestogen. Evidence suggesting a more favorable profile for micronized progesterone than medroxyprogesterone acetate is largely observational and remains incomplete ⁴.

Bioidentical and compounded. “Bioidentical” describes a molecule with the same structure as a hormone made by the body. FDA-approved estradiol and micronized progesterone are bioidentical. “Compounded” describes how a pharmacy makes a product. Compounded hormones are not FDA-approved, and potency can vary. ACOG recommends an FDA-approved product when one can meet the clinical need ⁵.

Is the estrogen patch safer than the pill?

Transdermal estrogen is associated with a lower blood-clot risk than oral estrogen in observational research ³. The best route still depends on personal risk, symptoms, cost, and preference. A patch does not make systemic therapy risk-free, and the comparison has not been established in a randomized head-to-head outcomes trial.

What Women Notice, and What a Strong Plan Tracks

Hot flashes and night sweats often improve within several weeks of starting systemic estrogen ¹. Local vaginal estrogen can take several weeks to improve dryness or painful sex. Response time varies, and persistent symptoms may need a dose, route, adherence, or diagnostic review.

MHT is not a weight-loss treatment. Weight and body composition can change during midlife for several reasons, including aging, activity, sleep, and the menopause transition. Evaluate those concerns separately instead of using a scale reading to judge whether MHT is working.

1. 1
   Symptoms

   Track the symptoms the treatment is intended to improve, such as hot flashes, sleep disruption, sexual discomfort, or urinary symptoms.
2. 2
   Risk context

   Review blood pressure, migraine and clot history, breast and uterine health, family history, and other medications.
3. 3
   Bone and body composition

   Assess bone health according to age and risk. A baseline scan is useful for some people, not a requirement for everyone starting MHT.
4. 4
   Dose and route

   Use the dose and route that address the treatment goal, then adjust when benefits, side effects, or health needs change.

A DEXA bone-density scan may be appropriate based on age, fracture history, medication use, and other risk factors. Unscheduled bleeding can occur early in treatment. Persistent, heavy, or new bleeding after a period without bleeding should be evaluated.

The WHI Trial and Its Modern Reframe

The Women's Health Initiative (WHI) changed menopause care after results from its combined-therapy trial were reported in 2002. Understanding what it tested helps prevent both dismissal and overgeneralization of its findings.

The combined arm tested oral conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA). Participants were about 63 years old on average. The regimen increased breast cancer, coronary events, stroke, and blood clots while reducing hip fractures ⁶. These findings apply directly to that regimen and population.

The estrogen-alone arm enrolled women who had undergone hysterectomy. It tested CEE without MPA and found more strokes, fewer fractures, and no increase in coronary heart disease ⁷. In long-term follow-up, estrogen alone was associated with 22% lower breast-cancer incidence. Combined therapy was associated with 28% higher incidence ⁸. These are relative effects from two different trial populations.

The WHI memory substudy found an increased dementia rate in women age 65 and older who received combined therapy ⁹. It did not test MHT as cognitive prevention in recently menopausal women. Current guidance does not recommend MHT to prevent cognitive decline ¹.

The WHI results remain central to counseling. They do not establish the outcomes of every modern product, route, dose, or starting age. They also do not support describing MHT as risk-free.

Timing: Why Starting Near Menopause Changes the Balance

Age and years since menopause affect the balance of benefits and risks. For many healthy people with bothersome symptoms, starting before age 60 or within 10 years of menopause can offer a favorable balance ¹, ². These thresholds guide an individual assessment; they do not make treatment appropriate for everyone below them.

The ELITE trial compared estradiol started less than six years after menopause with treatment started 10 or more years afterward. Estradiol slowed progression of carotid-artery wall thickness in the early group but not the late group ¹⁰. Coronary-artery calcium did not differ. The trial measured markers of artery disease, not heart attacks or strokes.

The broader timing hypothesis comes from age-stratified WHI analyses, other trials, and pooled evidence ¹¹. A Danish open-label trial in recently menopausal women reported fewer cardiovascular events, but the event count was small and the design had limitations ¹². The evidence supports more favorable counseling near menopause. It does not justify prescribing MHT to prevent cardiovascular disease.

The Benefits and Risks: Bone, Clots, Breast, and Heart

The main outcomes need to be considered separately. Route, regimen, timing, and baseline health do not affect every outcome in the same way.

Bone protection is well established. In the combined WHI arm, hip fractures were about one-third less frequent with treatment ⁶. Fewer fractures can preserve mobility and independence, but this does not show that MHT extends life.

Venous thromboembolism (VTE) means a blood clot in a deep vein or the lungs. In a large observational analysis, oral estrogen had 70% higher odds of VTE than transdermal estrogen ³. This relative comparison should not be treated as a randomized estimate or a guarantee that a patch is safe for everyone.

Across randomized trials in a 2024 meta-analysis, MHT increased stroke risk by 23% in relative terms and did not reduce major cardiovascular events ¹³. The absolute increase is smaller when baseline risk is low. This pooled result does not make every route or regimen identical.

Breast-cancer counseling must identify the regimen and population. WHI combined CEE plus MPA increased incidence, while CEE alone in women with hysterectomy reduced incidence and mortality ⁸. For the WHI CEE-plus-MPA regimen, the Menopause Society describes the attributable risk as fewer than one additional case per 1,000 women per year of use ¹.

MHT is not a treatment for preventing cardiovascular disease and is not a longevity drug. Pooled trial data found no significant change in mortality ¹³. About 18 years of WHI follow-up also found no excess mortality in either randomized arm ¹⁴. A result showing no excess deaths does not prove longer life.

What the 2025 and 2026 FDA Changes Mean

Recent FDA action changed how MHT risks appear in product labeling. The policy announcement and the first approved label changes happened on different dates.

On November 10, 2025, the FDA requested that manufacturers remove cardiovascular-disease, breast-cancer, and probable-dementia statements from boxed warnings ¹⁵. It kept cardiovascular and breast-cancer information elsewhere in systemic-product labeling. The agency also retained the endometrial-cancer boxed warning for systemic estrogen used alone. It requested language about considering treatment for moderate-to-severe symptoms before age 60 or within 10 years of menopause.

On February 12, 2026, the FDA approved updated labeling for the first six products ¹⁶. Products may therefore carry different label versions while manufacturers complete the process. The current label for the specific prescription remains the practical source for its warnings and instructions.

The label action did not establish MHT as a treatment to prevent dementia. A 2025 systematic review found no convincing evidence that MHT changes dementia risk in either direction, with certainty ranging from moderate to very low ¹⁷. A large observational study reported higher dementia rates, including among women who started treatment at younger ages ¹⁸. Current clinical guidance does not recommend MHT for cognitive prevention ¹.

The process drew criticism from former WHI investigators ¹⁹ and nine former members of the trial's safety-monitoring board ²⁰. They argued that warnings should continue to reflect randomized evidence and that MHT should not be promoted for chronic-disease prevention. Removing selected statements from a boxed warning does not remove all risks from the label.

Why did the FDA remove the black box warning on hormone therapy?

In November 2025, the FDA requested removal of cardiovascular-disease, breast-cancer, and probable-dementia statements from MHT boxed warnings ¹⁵. In February 2026, it approved updated labeling for a first group of six products ¹⁶. Other warnings and precautions remain, including the endometrial-cancer boxed warning for systemic estrogen used alone.

Where Menopause Hormone Therapy Fits in a Longevity Plan

MHT has a clear role in treating symptoms and preventing bone loss. Those benefits can improve sleep, comfort, function, and quality of life. They do not make MHT a general anti-aging treatment.

The strongest evidence supports relief of hot flashes and night sweats. Low-dose vaginal estrogen has a separate role in treating GSM. Systemic treatment prevents fractures, but cardiovascular evidence depends on timing and includes meaningful stroke and clot risks. Long-term WHI follow-up found no excess mortality. It did not show that MHT extends life.

Match the treatment to the problem. Local vaginal estrogen may be sufficient for painful sex or urinary symptoms, while severe hot flashes require a systemic option. Review the route, need for a progestogen, expected benefits, and relevant risks with a clinician. Persistent or new bleeding also needs a clear follow-up plan.

The companion articles cover recognizing perimenopause, starting treatment, and managing sexual symptoms in greater detail. These questions overlap, but each requires its own evaluation.

Blood biomarkers for longevity explains common cardiometabolic tests used in midlife. Thyroid optimization covers a condition that can overlap with menopause symptoms.